6 news items
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
BLRX
29 May 24
HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
BLRX
24 May 24
Motixafortide inhibits CXCR4, a chemokine receptor and a well validated therapeutic target that is over-expressed
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
BLRX
6 May 24
% to 75% of patients required more than one apheresis session to collect a target number of cells.2,3
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
BLRX
17 Apr 24
HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
BLRX
17 Apr 24
regimens and mobilization strategies, approximately 50% to 75% of patients required more than one apheresis session to collect a target number
711m b3zna5a
BLRX
26 Mar 24
HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.
- Prev
- 1
- Next